Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 09, 2024 13:59 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease,...
Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional PD1-IL18 Immunocytokine
April 17, 2023 06:00 ET
|
Bright Peak Therapeutics, Inc.
– Designed to deliver coordinated blockade of PD-1/PD-L1 pathway with targeted, enhanced IL-18 signaling to critical antitumor effector cells – – T cells co-expressing PD-1 and IL-18 receptors are...
Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022
November 09, 2022 07:00 ET
|
Bright Peak Therapeutics, Inc.
– BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity – – BPT331, a...
Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments
October 20, 2022 07:00 ET
|
Bright Peak Therapeutics, Inc.
– First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties — – Introduction of...
Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board
October 18, 2022 16:30 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO & BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering...
Bright Peak Therapeutics gibt Ernennung des führenden Krebsimmuntherapeuten Dr. Jon Wigginton zum Präsidenten für Forschung und Entwicklung bekannt
August 22, 2022 07:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO, Kalifornien und BASEL, Schweiz, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, ein Biotechnologieunternehmen, das Präzisionsimmuntherapien der nächsten Generation zur...
Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development
August 22, 2022 07:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and...
Bright Peak Therapeutics kündigt mehrere Präsentationen auf der Jahrestagung der American Association for Cancer Research (AACR) an
April 04, 2022 16:00 ET
|
Bright Peak Therapeutics, Inc.
-- Vortrag über die Entwicklung von Biologika der nächsten Generation mit Hilfe einer neuartigen chemischen Plattformtechnologie — -- Posterpräsentation über die cis-Aktivierung von PD-1+...
Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting
April 04, 2022 16:00 ET
|
Bright Peak Therapeutics, Inc.
--Oral Presentation to highlight the creation of next-generation biologics using a novel chemistry platform technology— --Poster presentation describing the cis-activation of PD-1+ effector T cells...
Bright Peak Therapeutics beruft Dr. Leena Gandhi, MD, in seinen Vorstand
February 28, 2022 16:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO, Kalifornien (USA) und BASEL (Schweiz), Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, ein Biotechnologieunternehmen, das Zytokin-Immuntherapien der nächsten Generation zur...